Regenxbio (RGNX) Operating Income (2016 - 2025)
Historic Operating Income for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$52.4 million.
- Regenxbio's Operating Income rose 1557.23% to -$52.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.9 million, marking a year-over-year increase of 3698.98%. This contributed to the annual value of -$233.3 million for FY2024, which is 1297.22% up from last year.
- According to the latest figures from Q3 2025, Regenxbio's Operating Income is -$52.4 million, which was up 1557.23% from -$63.3 million recorded in Q2 2025.
- In the past 5 years, Regenxbio's Operating Income ranged from a high of $313.6 million in Q4 2021 and a low of -$73.1 million during Q2 2023
- In the last 5 years, Regenxbio's Operating Income had a median value of -$62.1 million in 2024 and averaged -$37.3 million.
- Data for Regenxbio's Operating Income shows a peak YoY increase of 68451.1% (in 2021) and a maximum YoY decrease of 51106.73% (in 2021) over the last 5 years.
- Regenxbio's Operating Income (Quarter) stood at $313.6 million in 2021, then plummeted by 118.42% to -$57.8 million in 2022, then fell by 10.61% to -$63.9 million in 2023, then increased by 19.62% to -$51.4 million in 2024, then decreased by 2.03% to -$52.4 million in 2025.
- Its Operating Income was -$52.4 million in Q3 2025, compared to -$63.3 million in Q2 2025 and $12.1 million in Q1 2025.